S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
Log in

NASDAQ:IARTIntegra Lifesciences Stock Price, Forecast & News

$44.44
+3.02 (+7.29 %)
(As of 04/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$42.48
Now: $44.44
$44.82
50-Day Range
$36.67
MA: $48.44
$61.04
52-Week Range
$34.21
Now: $44.44
$65.09
Volume48,014 shs
Average Volume1.02 million shs
Market Capitalization$3.75 billion
P/E Ratio76.62
Dividend YieldN/A
Beta1.12
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Read More
Integra Lifesciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 billion
Cash Flow$4.40 per share
Book Value$16.50 per share

Profitability

Net Income$50.20 million

Miscellaneous

Employees4,000
Market Cap$3.75 billion
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.


Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

How has Integra Lifesciences' stock been impacted by COVID-19 (Coronavirus)?

Integra Lifesciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IART stock has decreased by 3.6% and is now trading at $44.44. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Integra Lifesciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Integra Lifesciences.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, April 22nd 2020. View our earnings forecast for Integra Lifesciences.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) released its earnings results on Wednesday, February, 19th. The life sciences company reported $0.68 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.67 by $0.01. The life sciences company had revenue of $395.13 million for the quarter, compared to analysts' expectations of $397.51 million. Integra Lifesciences had a net margin of 3.31% and a return on equity of 16.90%. The firm's revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period last year, the business earned $0.65 EPS. View Integra Lifesciences' earnings history.

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Integra Lifesciences's stock split on the morning of Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences issued an update on its FY20 earnings guidance on Wednesday, February, 19th. The company provided earnings per share (EPS) guidance of $3.00-3.05 for the period, compared to the Thomson Reuters consensus estimate of $3.00. The company issued revenue guidance of $1.55-1.57 billion, compared to the consensus revenue estimate of $1.59 billion.

What price target have analysts set for IART?

9 analysts have issued 12-month price targets for Integra Lifesciences' stock. Their forecasts range from $46.00 to $75.00. On average, they anticipate Integra Lifesciences' stock price to reach $62.20 in the next year. This suggests a possible upside of 40.0% from the stock's current price. View analysts' price targets for Integra Lifesciences.

Has Integra Lifesciences been receiving favorable news coverage?

Media coverage about IART stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Integra Lifesciences earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the life sciences company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIntegra Lifesciences.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a decrease in short interest in March. As of March 13th, there was short interest totaling 3,112,400 shares, a decrease of 13.3% from the February 27th total of 3,590,000 shares. Based on an average trading volume of 986,300 shares, the short-interest ratio is currently 3.2 days. Currently, 4.4% of the shares of the company are sold short. View Integra Lifesciences' Current Options Chain.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Intel (INTC), Activision Blizzard (ATVI), Micron Technology (MU), Netflix (NFLX), salesforce.com (CRM) and Applied Materials (AMAT).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the following people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $44.44.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $3.75 billion and generates $1.52 billion in revenue each year. The life sciences company earns $50.20 million in net income (profit) each year or $2.74 on an earnings per share basis. Integra Lifesciences employs 4,000 workers across the globe. View additional information about Integra Lifesciences.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is http://www.integralife.com/.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel